vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v13i3.1035vsp-199Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ КАНАКИНУМАБА У ПАЦИЕНТА С ТЯЖЕЛЫМ КРИОПИРИНАССОЦИИРОВАННЫМ СИНДРОМОМ (СИНДРОМ CINCA/NOMID)EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)СлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruАлексееваЕ. И.AlexeevaE. I.

Alexeeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I.M. Sechenov First MSMU; Head of the Rheumatologic Department of SCCH

alekatya@ya.ruСавостьяновК. В.Savost’yanovK. V.alekatya@ya.ruПушковА. А.PushkovA. A.alekatya@ya.ruНикитинА. Г.NikitinA. G.alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruВалиеваС. И.ValievaS. I.alekatya@ya.ruФетисоваА. Н.FetisovaA. N.alekatya@ya.ruПахомовА. В.PakhomovA. V.alekatya@ya.ruЖурковаН. В.ZhurkovaN. V.alekatya@ya.ruДенисоваР. В.DenisovaR. V.alekatya@ya.ruИсаеваК. Б.IsaevaK. B.alekatya@ya.ruЧистяковаЕ. Г.ChistyakovaE. G.alekatya@ya.ruНаучный центр здоровья детей, МоскваРоссияScientific Centre of Children Health, MoscowRussian FederationНаучный центр здоровья детей, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, Moscow I.M. Sechenov First Moscow State Medical UniversityRussian Federation201419062014133Вопросы современной педиатрии97103Copyright © Слепцова Т.В., Алексеева Е.И., Савостьянов К.В., Пушков А.А., Никитин А.Г., Бзарова Т.М., Валиева С.И., Фетисова А.Н., Пахомов А.В., Журкова Н.В., Денисова Р.В., Исаева К.Б., Чистякова Е.Г., 20142014Слепцова Т.В., Алексеева Е.И., Савостьянов К.В., Пушков А.А., Никитин А.Г., Бзарова Т.М., Валиева С.И., Фетисова А.Н., Пахомов А.В., Журкова Н.В., Денисова Р.В., Исаева К.Б., Чистякова Е.Г.Sleptsova T.V., Alexeeva E.I., Savost’yanov K.V., Pushkov A.A., Nikitin A.G., Bzarova T.M., Valieva S.I., Fetisova A.N., Pakhomov A.V., Zhurkova N.V., Denisova R.V., Isaeva K.B., Chistyakova E.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/199

Представлено наблюдение тяжелого течения криопирин-ассоциированного синдрома (синдрома CINCA / NOMID). Описано успешное применение моноклональных антител к интерлейкину 1ß — канакинумаба — у пациента с хроническим неврологическим кожным и суставным синдромом. Уже через 1 нед лечения полностью купировались лихорадка, сыпь и болевой синдром, уменьшились контрактуры в суставах. Через 8 нед терапии у ребенка практически полностью восстановились движения в пораженных суставах, мальчик начал самостоятельно стоять, говорить простые слова; снизились и нормализовались лабораторные показатели активности болезни (скорость оседания эритроцитов и С-реактивный белок). Через 12 нед ребенок стал ходить с поддержкой, говорить простые фразы. Приведенный клинический пример демонстрирует высокую эффективность канакинумаба у больного хроническим неврологическим кожным и суставным синдромом и свидетельствует о перспективности терапевтического применения блокатора интерлейкина 1ß у больных на ранних стадиях заболевания, до развития необратимой костно-хрящевой деструкции и тяжелого поражения центральной нервной системы. Нежелательных явлений на фоне терапии канакинумабом зарегистрировано не было.

детиаутовоспалительные синдромыкриопиринассоциированный синдромCINCA/NOMIDканакинумабchildrenautophologistic syndromescryopyrin-associated syndromeCINCA/NOMIDcanakinumabReferencesGattorno M. Vopr. sovr. pediatrii — Current pediatrics. 2014; 13 (2): 55–64.Gattorno M. Vopr. sovr. pediatrii — Current pediatrics. 2014; 13 (2): 55–64.Agostini L., Martinon F., Burns K., McDermott M. F., Hawkins P. N., Tschopp J. NALP3 forms an IL-1beta processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity. 2004; 20: 319–325.Agostini L., Martinon F., Burns K., McDermott M. F., Hawkins P. N., Tschopp J. NALP3 forms an IL-1beta processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity. 2004; 20: 319–325.Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–1515.Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–1515.Gattorno M., Tassi S., Carta S., Delfino L., Ferlito F., Pelagatti M. A. et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007; 56: 3138–3148.Gattorno M., Tassi S., Carta S., Delfino L., Ferlito F., Pelagatti M. A. et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007; 56: 3138–3148.Goldbach-Mansky R., Dailey N. J., Canna S. W., Gelabert A., Jones J., Rubin B. I. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 2006; 355: 581–592.Goldbach-Mansky R., Dailey N. J., Canna S. W., Gelabert A., Jones J., Rubin B. I. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 2006; 355: 581–592.Rosengren S., Mueller J. L., Anderson J. P., Niehaus B. L., Misaghi A., Anderson S. et al. Monocytes from familial cold autoinflammatory syndrome patients areactivated by mild hypothermia. J. Allergy Clin. Immunol. 2007; 119: 991–996.Rosengren S., Mueller J. L., Anderson J. P., Niehaus B. L., Misaghi A., Anderson S. et al. Monocytes from familial cold autoinflammatory syndrome patients areactivated by mild hypothermia. J. Allergy Clin. Immunol. 2007; 119: 991–996.Stack J. H., Beaumont K., Larsen P. D., Straley K. S., Henkel G. W., Randle J. C. et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 2005; 175: 2630–2634.Stack J. H., Beaumont K., Larsen P. D., Straley K. S., Henkel G. W., Randle J. C. et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 2005; 175: 2630–2634.Tassi S., Carta S., Delfino L., Caorsi R., Martini A., Gattorno M. et al. Altered redoxstate of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc. Natl. Acad. Sci. USA. 2010; 107: 9789–9794.Tassi S., Carta S., Delfino L., Caorsi R., Martini A., Gattorno M. et al. Altered redoxstate of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc. Natl. Acad. Sci. USA. 2010; 107: 9789–9794.Hedrich C. M., Bruck N., Paul D., Hahn G., Gahr M., RosenWolff A. «Mutationnegative» familial cold autoinflammatory syndrome (FCAS) in an 8-year-oldboy: clinical course and functional studies. Rheumatol. Int. 2012; 32: 2629–2636.Hedrich C. M., Bruck N., Paul D., Hahn G., Gahr M., RosenWolff A. «Mutationnegative» familial cold autoinflammatory syndrome (FCAS) in an 8-year-oldboy: clinical course and functional studies. Rheumatol. Int. 2012; 32: 2629–2636.URL: http://www.printo.it/eurofever/eurofever_results.aspURL: http://www.printo.it/eurofever/eurofever_results.aspArostegui J. I., Lopez Saldana M. D., Pascal M., Clemente D., Aymerich M., Balaguer F., Goel A., Fournier del Castillo C., Rius J., Plaza S., Lopez Robledillo J. C., Juan M., Ibanez M., Yague J. A somatic NLRP3 mutation as a cause of sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases. Arthritis Rheum. 2010; 62 (4): 1158–1166.Arostegui J. I., Lopez Saldana M. D., Pascal M., Clemente D., Aymerich M., Balaguer F., Goel A., Fournier del Castillo C., Rius J., Plaza S., Lopez Robledillo J. C., Juan M., Ibanez M., Yague J. A somatic NLRP3 mutation as a cause of sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases. Arthritis Rheum. 2010; 62 (4): 1158–1166.Hoffman H. M., Mueller J. L., Broide D. H., Wanderer A. A., Kolodner R. D. Mutation of a new gene encoding a putative pyrinlike protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature Genet. 2001; 29: 301–305.Hoffman H. M., Mueller J. L., Broide D. H., Wanderer A. A., Kolodner R. D. Mutation of a new gene encoding a putative pyrinlike protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature Genet. 2001; 29: 301–305.Tanaka N., Izawa K., Saito M. K. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011; 63: 3625–3632.Tanaka N., Izawa K., Saito M. K. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 2011; 63: 3625–3632.Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B., Leslie K. S., Hachulla E., Quartier P. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 2009; 360: 2416–2425.Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B., Leslie K. S., Hachulla E., Quartier P. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 2009; 360: 2416–2425.Kitley J. L., Lachmann H. J., Pinto A., Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010; 74: 1267–1270.Kitley J. L., Lachmann H. J., Pinto A., Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010; 74: 1267–1270.Kone-Paut I., Lachmann H. J., Kuemmerle-Deschner J. B., Hachulla E., Leslie K. S., Mouy R. et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res. Ther. 2011; 13: 202.Kone-Paut I., Lachmann H. J., Kuemmerle-Deschner J. B., Hachulla E., Leslie K. S., Mouy R. et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res. Ther. 2011; 13: 202.Kuemmerle-Deschner J. B., Ramos E., Blank N., Roesler J., Felix S. D., Jung T. et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther. 2011; 13: 34.Kuemmerle-Deschner J. B., Ramos E., Blank N., Roesler J., Felix S. D., Jung T. et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther. 2011; 13: 34.Kuemmerle-Deschner J. B., Hachulla E., Cartwright R., Hawkins P. N., Tran T. A., Bader-Meunier B. et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 2011; 70: 2095–2102.Kuemmerle-Deschner J. B., Hachulla E., Cartwright R., Hawkins P. N., Tran T. A., Bader-Meunier B. et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 2011; 70: 2095–2102.Ahmadi N., Brewer C. C., Zalewski C., King K. A., Butman J. A., Plass N. et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologicmanifestations. Otolaryngol. Head Neck Surg. 2011; 145: 295–302.Ahmadi N., Brewer C. C., Zalewski C., King K. A., Butman J. A., Plass N. et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologicmanifestations. Otolaryngol. Head Neck Surg. 2011; 145: 295–302.Klein A. K., Horneff G. Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra. Klin. Padiatr. 2011; 222: 266–268.Klein A. K., Horneff G. Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra. Klin. Padiatr. 2011; 222: 266–268.Ait-Abdesselam T., Lequerre T., Legallicier B., Francois A., Le Loet X., VittecoqO. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine. 2011; 77: 616–617.Ait-Abdesselam T., Lequerre T., Legallicier B., Francois A., Le Loet X., VittecoqO. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine. 2011; 77: 616–617.Kuemmerle-Deschner J. B., Tyrrell P. N., Koetter I., Wittkowski H., Bialkowski A., Tzaribachev N. et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011; 63: 840–849.Kuemmerle-Deschner J. B., Tyrrell P. N., Koetter I., Wittkowski H., Bialkowski A., Tzaribachev N. et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011; 63: 840–849.Thornton B. D., Hoffman H. M., Bhat A., Don B. R. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin1 receptor antagonist. Am. J. Kidney Dis. 2007; 49: 477–481.Thornton B. D., Hoffman H. M., Bhat A., Don B. R. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin1 receptor antagonist. Am. J. Kidney Dis. 2007; 49: 477–481.

The authors declare that there are no conflicts of interest present.